Loading…
Mettler Toledo International Inc/
Mettler Toledo International Inc/ (MTD) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Greifensee, Switzerland and has 16,600 employees. The company is worth $33.75B and trades at 38.0x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $4.03B in fiscal 2025, up 4.0% from the year before. Net income was $869.19M. The share price is within 3% of its 52-week high. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $164.78M. In that quarter, 3 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +7.1% over 5Y.
today you would have $1,095.49▲ +9.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 18 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1,394.19 | $1,223.68 | $1,212.96 | $1,445.45 | $1,697.21 | $1,139.68 | $793.28 | $565.58 | $619.52 | $418.56 | $339.13 | $302.46 | $242.59 | $193.30 | $147.71 | $151.21 | $104.99 | $67.40 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings growing 11.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 28.9 across this company’s own years on record.
Cash flow growing 11.0% a year for 10 years, discounted at 10%, then 2.5% forever.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZTSZoetis Inc. | $82.00 | 13.5x | 10.8x | 2.59% | 64.91% | $33.88B |
| ALCAlcon Inc | $70.63 | 51.2x | 1.6x | 0.51% | 2.94% | $34.14B |
| CNCCentene Corp | $71.24 | — | 1.6x | 0.00% | -20.36% | $35.19B |
| GEHCGE HealthCare Technologies Inc. | $71.42 |
| P/E | 28.9x | 33.2x | 30.2x | 33.8x | 37.6x | 51.8x | 45.8x | 35.3x | 28.4x | 43.5x | 29.4x | 27.2x | 26.4x | 24.4x | 21.1x | 18.0x | 22.2x | 20.9x | 11.6x |
| P/S | 4.6x | 7.0x | 6.6x | 6.9x | 8.2x | 10.4x | 8.6x | 6.3x | 4.8x | 5.8x | 4.3x | 3.8x | 3.4x | 3.0x | 2.5x | 2.0x | 2.5x | 2.1x | 1.2x |
| P/B | 15.8x | — | — | — | 1288.8x | 225.8x | 94.4x | 45.3x | 23.8x | 28.8x | 25.0x | 15.8x | 11.8x | 7.6x | 7.1x | 6.0x | 6.3x | 5.0x | 4.7x |
| EPS | $42.05 | $40.48 | $35.90 | $38.41 | $32.78 | $24.91 | $22.47 | $19.88 | $14.24 | $14.22 | $12.48 | $11.44 | $9.96 | $9.14 | $8.21 | $6.80 | $5.03 | $5.79 |
| Profit margin | 15.03% | 21.59% | 22.29% | 20.82% | 22.26% | 20.68% | 19.54% | 18.65% | 17.46% | 13.80% | 15.32% | 14.73% | 13.61% | 12.87% | 12.42% | 11.67% | 11.80% | 9.98% | 10.28% |
| ROE | 60.78% | — | — | — | 3519.15% | 448.59% | 213.23% | 133.35% | 86.87% | 68.70% | 88.37% | 60.78% | 47.00% | 32.74% | 35.16% | 34.50% | 30.09% | 24.27% | 40.29% |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
4 methods answered, across 2 families.
Room for errors in the reported numbers.
-43.2% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 15.9x |
| 2.9x |
| 0.22% |
| 19.38% |
| $32.26B |
| RMDResmed Inc | $253.06 | 23.6x | 5.5x | 1.04% | 24.27% | $35.59B |
| RPRXRoyalty Pharma plc | $63.75 | 33.0x | 4.2x | 1.47% | 13.96% | $36.84B |
